OncoResponse
Facts
- HQ
- Seattle
- Sectors
- Biotech, Immunotherapy, Biopharmaceuticals
- Founded
- 2016 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- OncoResponse Inc Seattle business license
- Total raised
- $84M SEC Form D filings Total of this company's SEC Form D filings
- Last round
- $13.9M · May 2023 SEC Form D
Recent coverage
Front-page news, podcasts and videos about OncoResponse
OncoResponse Raises $27M to Advance Antibody-Based Cancer Immunotherapies OR502 and OR2805
Seattle biotech firm OncoResponse secured $27 million to advance testing of its antibody-based cancer immunotherapy candidates OR502 and OR2805. The funding includes a $13 million grant from the Cancer Prevention and Research Institute of Texas and $14 million from investors led by RiverVest Venture Partners.
Just–Evotec Biologics opens 130,000 sq ft Redmond J.POD to manufacture COVID‑19 antibody therapeutics for U.S. Defense
Just–Evotec Biologics opened a 130,000 sq ft J.POD drug manufacturing facility in Redmond, Washington that uses continuous, autonomous bioprocessing to design, develop and produce antibody therapeutics more efficiently and at lower cost. The plant will manufacture antibodies for the U.S. Department of Defense to potentially treat COVID-19 and supports both small- and large-scale production for biotech customers globally.
People
-
Clifford Stocks Founder, Executive Officer, Director
